Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease

NCT01048229 is registered in ClinicalTrials.gov with Qualissima as lead sponsor.

NCT NCT01048229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01048229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease
Lead sponsor
Qualissima
Phase
Phase 4
Overall status
Terminated
Start date
October 31, 2008
Completion date
March 31, 2010
Enrollment
112 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

early-stage parkinson's disease